R&D channel feed – Endpoints News

R&D channel feed

Shire hit by a setback as Hunter syndrome drug fails late-stage study

8 years ago

Severe job cuts at Teva incite massive worker strikes, shutting Israel down

8 years ago

Allergan and Gedeon Richter ready to knock on FDA's door after a positive PhIII for cariprazine in bipolar depression

8 years ago

One of Merck's pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK

8 years ago

Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires

8 years ago

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs

8 years ago

The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate

8 years ago

Teva axing 14,000 workers, putting R&D and manufacturing facilities on the block in massive restructuring

8 years ago

NEA leads a big syndicate on $100M mega-round for Allakos

8 years ago

Daiichi ditches Nektar following cancer drug flop

8 years ago

Sanofi faces a make-or-break year, saying it’s ready to put a 3-prong R&D strategy to a pivotal test

8 years ago

Teva sharpens ax, preps brutal cuts in R&D and across the group in face of crushing debt

8 years ago

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

8 years ago

Aduro buries another cancer vaccine after CRS-207 joins the lineup of clinical disasters

8 years ago

#ASH17: AbbVie, Roche boast stellar PhIII leukemia data for a “breakthrough” combo with blockbuster ambitions

8 years ago

GSK offers encouraging data on BCMA-targeting armed antibody, setting stage for a return to late-stage cancer studies

8 years ago

#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky

8 years ago

#ASH17: Syros eviscerated by investor backlash as lead drug flails badly in PhII

8 years ago

Can GSK’s new R&D strategy resuscitate the worst performer in Big Pharma?

8 years ago

#ASH17: Verastem's AbbVie castoff is headed for the FDA — even after missing overall survival goal

8 years ago

#ASH17: Blueprint elbows its way to center ring with early data and a plan to seek quick FDA OK

8 years ago

#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?

8 years ago

#ASH17: The BCMA-targeted CAR-T bb2121 from bluebird and Celgene takes a star turn in the spotlight

8 years ago

#ASH17: Roche unveils stellar PhII DLBCL data for one of its top hematology drugs in the pipeline

8 years ago

First page Previous page 284 285 286287288 289 290 Next page Last page